The US saw a 76% treatment success rate for HIV-positive tuberculosis in 2023. Projections show a steady improvement: 76% in 2024, rising incrementally to 78% by 2027 and staying at 78% in 2028. This reflects a modest upward trend. Analyzing data from 2024 to 2028, the average compound annual growth rate (CAGR) signals a positive trend, though slight.
Looking ahead, factors affecting this trend include advancements in treatment protocols, accessibility to healthcare, and patient adherence to treatment plans. Monitoring policy shifts and funding allocations for disease control will be crucial in projecting future success rates.
